Literature DB >> 11930329

Monocyte chemoattractant protein-2 (CC chemokine ligand 8) inhibits replication of human immunodeficiency virus type 1 via CC chemokine receptor 5.

Otto O Yang1, Eduardo A Garcia-Zepeda, Bruce D Walker, Andrew D Luster.   

Abstract

CC chemokine receptor 5 (CCR5) is a coreceptor for cellular entry of monocyte-tropic (R5) strains of human immunodeficiency virus (HIV) type 1, which has been implicated as the predominant phenotype of HIV in early infection. The CCR5 agonists macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES (regulated on activation, normally T cell-expressed and -secreted) have been shown to block replication of R5 virus in vitro and have gained attention as potential antiviral factors. However, a few reports have suggested that other chemokines may also block R5 HIV-1, including monocyte chemoattractant protein (MCP)-2 (CC chemokine ligand 8). We demonstrate that MCP-2 specifically inhibits replication of R5 HIV-1 and that this activity is additive to that of RANTES. Furthermore, MCP-2 induces a robust, pertussis toxin-sensitive calcium flux in primary lymphocytes, and cross-desensitization studies indicate that MCP-2 acts via CCR5. These data confirm that MCP-2 is a ligand for CCR5 on CD4(+) lymphocytes and can specifically block R5 HIV-1.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11930329     DOI: 10.1086/339678

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Morphine affects HIV-induced inflammatory response without influencing viral replication in human monocyte-derived macrophages.

Authors:  Rajnish S Dave
Journal:  FEMS Immunol Med Microbiol       Date:  2012-03

2.  In vitro suppression of human immunodeficiency virus type 1 replication by measles virus.

Authors:  Mayra García; Xiao-Fang Yu; Diane E Griffin; William J Moss
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27.

Authors:  J Mohamad Fakruddin; Richard A Lempicki; Robert J Gorelick; Jun Yang; Joseph W Adelsberger; Alfonso J Garcia-Pineres; Ligia A Pinto; H Clifford Lane; Tomozumi Imamichi
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

4.  Short Communication: Expression of APOBEC3G and Interferon Gamma in Pleural Fluid Mononuclear Cells from HIV/TB Dual Infected Subjects.

Authors:  Zahra Toossi; Qinglai Meng; Htin Aung; Shigou Liu; Harriet Mayanja-Kizza; Christina S Hirsch
Journal:  AIDS Res Hum Retroviruses       Date:  2015-06-04       Impact factor: 2.205

5.  CCL8/MCP-2 is a target for mir-146a in HIV-1-infected human microglial cells.

Authors:  Slava Rom; Inna Rom; Giovanni Passiatore; Marco Pacifici; Sujatha Radhakrishnan; Luis Del Valle; Sergio Piña-Oviedo; Kamel Khalili; Davide Eletto; Francesca Peruzzi
Journal:  FASEB J       Date:  2010-02-24       Impact factor: 5.191

6.  Reconstitution of human immunodeficiency virus-induced neurodegeneration using isolated populations of human neurons, astrocytes, and microglia and neuroprotection mediated by insulin-like growth factors.

Authors:  Jianbin Wang; Dana Gabuzda
Journal:  J Neurovirol       Date:  2006-12       Impact factor: 2.643

7.  Blood-based inflammation biomarkers of neurocognitive impairment in people living with HIV.

Authors:  Naomi Swanta; Subhash Aryal; Vicki Nejtek; Sangeeta Shenoy; Anuja Ghorpade; Kathleen Borgmann
Journal:  J Neurovirol       Date:  2020-03-19       Impact factor: 2.643

Review 8.  Chemokine-Derived Peptides: Novel Antimicrobial and Antineoplasic Agents.

Authors:  Julio Valdivia-Silva; Jaciel Medina-Tamayo; Eduardo A Garcia-Zepeda
Journal:  Int J Mol Sci       Date:  2015-06-08       Impact factor: 5.923

9.  PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads.

Authors:  Edward Seung; Timothy E Dudek; Todd M Allen; Gordon J Freeman; Andrew D Luster; Andrew M Tager
Journal:  PLoS One       Date:  2013-10-21       Impact factor: 3.240

10.  Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment.

Authors:  Henk-Jan van den Ham; Jason D Cooper; Jakub Tomasik; Sabine Bahn; Joeri L Aerts; Albert D M E Osterhaus; Rob A Gruters; Arno C Andeweg
Journal:  PLoS One       Date:  2018-02-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.